Ended third quarter with $725.1 million in cash, cash equivalents, and marketable securities providing runway into the second half of 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MORF:
- Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
- Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
- Biotech Alert: Searches spiking for these stocks today
- Morphic price target lowered to $52 from $106 at BMO Capital
- Morphic (NASDAQ:MORF) Resumes Slide After CEO Takes Temporary Leave